image
Healthcare - Biotechnology - NASDAQ - US
$ 2.53
7.2 %
$ 58.7 M
Market Cap
-1.31
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one INMB stock under the worst case scenario is HIDDEN Compared to the current market price of 2.53 USD, INmune Bio, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one INMB stock under the base case scenario is HIDDEN Compared to the current market price of 2.53 USD, INmune Bio, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one INMB stock under the best case scenario is HIDDEN Compared to the current market price of 2.53 USD, INmune Bio, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart INMB

image
$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0$7.0$7.0$6.0$6.0$5.0$5.0$4.0$4.0$3.0$3.0$2.0$2.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
14 K REVENUE
-90.97%
-42.6 M OPERATING INCOME
-43.35%
-42.1 M NET INCOME
-40.24%
-33.4 M OPERATING CASH FLOW
-178.47%
0 INVESTING CASH FLOW
0.00%
18.2 M FINANCING CASH FLOW
531.03%
50 K REVENUE
0.00%
-9.9 M OPERATING INCOME
-4.63%
-9.74 M NET INCOME
-5.65%
-6.82 M OPERATING CASH FLOW
38.04%
0 INVESTING CASH FLOW
0.00%
5.27 M FINANCING CASH FLOW
353.80%
Balance Sheet INmune Bio, Inc.
image
Current Assets 22.7 M
Cash & Short-Term Investments 20.9 M
Receivables 1.41 M
Other Current Assets 331 K
Non-Current Assets 16.9 M
Long-Term Investments 0
PP&E 307 K
Other Non-Current Assets 16.6 M
52.88 %3.56 %41.94 %Total Assets$39.6m
Current Liabilities 7.22 M
Accounts Payable 6.56 M
Short-Term Debt 140 K
Other Current Liabilities 517 K
Non-Current Liabilities 244 K
Long-Term Debt 244 K
Other Non-Current Liabilities 0
87.93 %6.93 %3.27 %Total Liabilities$7.5m
EFFICIENCY
Earnings Waterfall INmune Bio, Inc.
image
Revenue 14 K
Cost Of Revenue 0
Gross Profit 14 K
Operating Expenses 42.6 M
Operating Income -42.6 M
Other Expenses -553 K
Net Income -42.1 M
5m5m00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)(45m)(45m)14k014k(43m)(43m)553k(42m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
-304535.71% OPERATING MARGIN
-304535.71%
-300585.71% NET MARGIN
-300585.71%
-131.11% ROE
-131.11%
-106.37% ROA
-106.37%
-131.26% ROIC
-131.26%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis INmune Bio, Inc.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)(45m)(45m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -42.1 M
Depreciation & Amortization 553 K
Capital Expenditures 0
Stock-Based Compensation 7.6 M
Change in Working Capital 1.04 M
Others 1.46 M
Free Cash Flow -33.4 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets INmune Bio, Inc.
image
Wall Street analysts predict an average 1-year price target for INMB of $22 , with forecasts ranging from a low of $22 to a high of $22 .
INMB Lowest Price Target Wall Street Target
22 USD 769.57%
INMB Average Price Target Wall Street Target
22 USD 769.57%
INMB Highest Price Target Wall Street Target
22 USD 769.57%
Price
Max Price Target
Min Price Target
Average Price Target
222220201818161614141212101088664422Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 7
6. Ownership
Insider Ownership INmune Bio, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
348 K USD 2
9-12 MONTHS
7. News
INmune Bio: Thinking Through XPro's MINDFuL Data In Early Alzheimer's INmune Bio's XPro missed its Phase II primary endpoint, but subgroup data and safety profile suggest potential for targeted Alzheimer's patients with neuroinflammation. Despite the setback, I see significant upside from XPro and CORDStrom, with blockbuster potential if approved, given INMB's tiny current market cap. Risks include uncertain XPro efficacy, need for more capital, and dilution; I maintain a 2/5 conviction rating and keep INMB in my speculative portfolio. seekingalpha.com - 1 week ago
'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday Former hedge fund manager Martin Shkreli has issued a stark warning on the near-term trajectory of a biotech startup, just days after it witnessed a surge. benzinga.com - 1 week ago
INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Boca Raton, Florida, June 30, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it has closed its registered direct offering, announced on June 27, 2025, (the "Offering") for the purchase and sale of 3,000,000 shares of its common stock at a purchase price of $6.30 per share, priced at-the-market under Nasdaq rules. globenewswire.com - 1 week ago
INmune Bio shares tumble as Alzheimer's drug falls short in mid-stage trial INmune Bio Inc (NASDAQ:INMB) shares plummeted almost 60% following disappointing results from a Phase 2 clinical trial of its experimental Alzheimer's drug, XPro. The drug failed to meet the primary cognitive endpoint in the overall intent-to-treat population, meaning it did not significantly improve cognitive function over six months compared to placebo in early Alzheimer's patients. proactiveinvestors.com - 1 week ago
Alzheimer's Setback Hits INmune Bio Stock, But FDA Hopes Remain INmune Bio Inc. INMB stock is trading lower on Monday, with a session volume of 23.2 million, compared to the average volume of 1.45 million, as per data from Benzinga Pro. benzinga.com - 1 week ago
INmune Bio's Alzheimer's drug fails to meet main goal in mid-stage study INmune Bio said on Monday its experimental Alzheimer's drug failed to improve cognitive functions in patients with early stages of the mind-robbing disease in a mid-stage study, sending its shares plunging nearly 59% in premarket trading. reuters.com - 1 week ago
INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer's Disease In the Phase 2 MINDFuL trial of XPro™ in patients with early Alzheimer's Disease (AD) with biomarkers of inflammation, the modified intent-to-treat (mITT) population (n=200) did not meet the primary cognitive endpoint (EMACC), however in a predefined population of amyloid-positive early AD patients with two or more biomarkers of inflammation (n=100), a benefit of XPro™ treatment over placebo was observed in cognitive, behavioral and biological endpoints. globenewswire.com - 1 week ago
INmune Bio: Finding Pay Dirt In Alzheimer's? INmune Bio is working on a drug for Alzheimer's, with a critical phase 2 readout to be announced. It is unclear whether this will be positive or negative. Other potential drug candidates could help pick up the slack if MINDFuL is a dud. seekingalpha.com - 2 weeks ago
INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Boca Raton, Florida, June 27, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it has entered into securities purchase agreements with two healthcare focused institutional investors for the purchase and sale of 3,000,000 shares of its common stock in a registered direct offering (the "Offering") at a purchase price of $6.30 per share, priced at-the-market under Nasdaq rules. globenewswire.com - 2 weeks ago
INmune Bio Stock Soars Friday On Alzheimer's Treatment Hopes INmune Bio Inc. INMB stock is trading higher on Friday, with a session volume of 10.26 million compared to the average volume of 519.5K, per data from Benzinga Pro. benzinga.com - 2 weeks ago
INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer's on Monday, June 30th Company to host a conference call to discuss results at 8:00am EDT on June 30, 2025 Boca Raton, Florida, June 26, 2025 (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, will host a conference call on Monday, June 30 beginning at 8:00am EDT to present top line data from the Phase 2 MINDFuL trial in early Alzheimer's Disease. MINDFuL Results Call Information: To participate in this event, dial approximately at least 10 minutes before the beginning of the call or use the webcast link below. globenewswire.com - 2 weeks ago
INmune Bio: Imminent Phase 2 Alzheimer's Readout Of Unique Asset Presents Interesting Speculative Opportunity INmune Bio offers a high-risk, high-reward opportunity ahead of its Phase 2 Alzheimer's readout. Lead asset XPro1595's mechanism of selectively targeting soluble TNF (sTNF) has strong preclinical, mechanistic, and limited but encouraging Phase 1b data. If XPro1595 delivers positive results, it could validate a new approach in Alzheimer's and other inflammatory diseases, but the investment remains speculative due to clinical and market risks. seekingalpha.com - 3 weeks ago
8. Profile Summary

INmune Bio, Inc. INMB

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 58.7 M
Dividend Yield 0.00%
Description INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Contact 225 NE Mizner Boulevard, Boca Raton, FL, 33432 https://www.inmunebio.com
IPO Date Feb. 4, 2019
Employees 13
Officers Dr. Mark William Lowdell Ph.D. Chief Scientific Officer & Chief Manufacturing Officer Dr. Raymond Joseph Tesi M.D. Co-Founder, President, Chief Executive Officer, Chief Medical Officer & Chairman Mr. David J. Moss M.B.A. Chief Financial Officer, Treasurer & Secretary Mr. Joshua S. Schoonover Esq. General Counsel